AlzChem Group AG

BRSE:ACT Stock Report

Market Cap: CHF 1.8b

AlzChem Group Valuation

Is ACT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ACT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ACT (CHF160.37) is trading below our estimate of future cash flow value (CHF288)

Significantly Below Future Cash Flow Value: ACT is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACT?

Key metric: As ACT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ACT. This is calculated by dividing ACT's market cap by their current earnings.
What is ACT's PE Ratio?
PE Ratio28.7x
Earnings€66.82m
Market Cap€1.92b

Price to Earnings Ratio vs Peers

How does ACT's PE Ratio compare to its peers?

The above table shows the PE ratio for ACT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.3x
EMSN EMS-CHEMIE HOLDING
35x4.70%CHF 16.3b
SIKA Sika
23.8x9.21%CHF 24.9b
GIVN Givaudan
27.4x5.67%CHF 29.4b
002741 Guangdong Guanghua Sci-Tech
115xn/aCN¥13.8b
ACT AlzChem Group
28.7x18.65%CHF 1.9b

Price-To-Earnings vs Peers: ACT is good value based on its Price-To-Earnings Ratio (28.7x) compared to the peer average (50.3x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does ACT's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
ACT 28.7xIndustry Avg. 19.0xNo. of Companies10PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ACT is expensive based on its Price-To-Earnings Ratio (28.7x) compared to the European Chemicals industry average (19x).

Price to Earnings Ratio vs Fair Ratio

What is ACT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ACT's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 160.37
CHF 185.23
+15.50%
11.78%CHF 235.68CHF 162.95n/a7
Jun ’27n/a
CHF 175.66
0%
4.40%CHF 182.91CHF 161.88n/a6
May ’27n/a
CHF 175.17
0%
4.75%CHF 183.22CHF 162.15n/a6
Apr ’27n/a
CHF 168.12
0%
5.43%CHF 179.14CHF 157.32n/a6
Mar ’27n/a
CHF 163.54
0%
5.53%CHF 177.22CHF 149.96n/a6
Feb ’27n/a
CHF 164.87
0%
4.54%CHF 173.96CHF 153.74n/a5
Jan ’27n/a
CHF 167.17
0%
3.33%CHF 173.46CHF 160.73n/a4
Dec ’26n/a
CHF 155.75
0%
7.82%CHF 172.44CHF 139.81n/a5
Nov ’26n/a
CHF 151.28
0%
10.47%CHF 171.60CHF 129.86n/a5
Oct ’26n/a
CHF 144.55
0%
11.51%CHF 173.38CHF 126.71n/a5
Sep ’26n/a
CHF 144.55
0%
11.51%CHF 173.38CHF 126.71n/a5
Aug ’26n/a
CHF 125.43
0%
21.49%CHF 171.58CHF 89.96n/a5
Jul ’26n/a
CHF 109.55
0%
13.98%CHF 135.30CHF 90.51n/a5
Jun ’26n/a
CHF 109.55
0%
13.98%CHF 135.30CHF 90.51n/a5
May ’26n/a
CHF 95.80
0%
14.08%CHF 112.28CHF 80.47n/a5
Apr ’26n/a
CHF 98.23
0%
14.08%CHF 115.14CHF 82.52n/a5
Mar ’26n/a
CHF 71.39
0%
5.25%CHF 76.78CHF 67.42n/a5
Feb ’26n/a
CHF 68.82
0%
2.79%CHF 71.91CHF 66.80n/a4
Jan ’26n/a
CHF 68.82
0%
2.79%CHF 71.91CHF 66.80n/a4
Dec ’25n/a
CHF 67.71
0%
5.25%CHF 72.21CHF 62.42n/a4
Nov ’25n/a
CHF 67.41
0%
4.12%CHF 70.44CHF 62.92n/a4
Oct ’25n/a
CHF 58.62
0%
7.87%CHF 65.03CHF 53.55n/a4
Sep ’25n/a
CHF 58.62
0%
7.87%CHF 65.03CHF 53.55n/a4
Aug ’25n/a
CHF 50.95
0%
8.74%CHF 58.64CHF 48.08n/a4
Jul ’25n/a
CHF 50.06
0%
2.82%CHF 52.41CHF 48.96n/a4
Jun ’25n/a
CHF 48.53
0%
11.30%CHF 53.63CHF 39.29n/a4
CHF 170.36
Fair Value
5.9% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 20:40
End of Day Share Price 2026/06/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AlzChem Group AG is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard OrgonasBerenberg
Manuela StuerzerDeutsche Bank
Constantin HesseJefferies LLC